Get the Stockscreener App
69.51
1.00%
0.69
Dexcom Inc stock is traded at $69.51, with a volume of 2.60M.
It is up +1.00% in the last 24 hours and down -2.13% over the past month.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$68.82
Open:
$68.97
24h Volume:
2.60M
Relative Volume:
0.52
Market Cap:
$27.64B
Revenue:
$3.93B
Net Income/Loss:
$666.90M
P/E Ratio:
76.38
EPS:
0.91
Net Cash Flow:
$665.50M
1W Performance:
+1.31%
1M Performance:
-2.13%
6M Performance:
-47.21%
1Y Performance:
-33.94%
1-Day Range:
$68.14
$69.90
1-Week Range:
$66.86
$71.56
52-Week Range:
$62.34
$142.00
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DXCM STOCK ALERT: DexCom, Inc. Investors are Notified of Imminent October 21 Deadline in Class Action; Inform BFA Law if you Incurred Losses (Nasdaq:DXCM) - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - PR Newswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Kilgore News Herald
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200 - The Motley Fool
DXCM Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc. - Markets Insider
ROSEN, A LONGSTANDING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - ForexTV.com
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
ROSEN, A LONGSTANDING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - GlobeNewswire Inc.
DXCM STOCK ALERT: A Class Action is Pending Against DexCom, Inc. for Securities Fraud; Contact BFA Law before October 21 Court Deadline if You Lost Money - AccessWire
Faruqi & Faruqi Reminds DexCom Investors of the Pending - GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Is DexCom Stock Underperforming The S&P 500? - Barchart
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire
DXCM INVESTOR DEADLINE: DexCom, Inc. Investors that Lost - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. LawsuitDXCM - PR Newswire
DexCom (DXCM) Sales Force Changes Drove Poor Execution, Disappointing Outlook, & 40% Stock Drop, Class Action Pending – Hagens Berman - ForexTV.com
mHealth Market Next Big Thing | Major Giants- Fitbit, DEXCOM, Boston Scientific - Newstrail
DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - AccessWire
DexCom Inc. stock rises Thursday, still underperforms market - MarketWatch
Wall Street Analyst Downgrade Dexcom Inc [DXCM]. What else is Wall St. saying - The DBT News
DexCom (DXCM) Sales Force Changes Drove Poor Execution, - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - The Malaysian Reserve
Dexcom data: CGM for type 2 diabetes without insulin treatment - BioWorld Online
Prudential PLC Boosts Stock Holdings in DexCom, Inc. (NASDAQ:DXCM) - Defense World
A stock that deserves closer examination: Dexcom Inc (DXCM) - US Post News
3 Reasons DexCom Looks Like a No-Brainer Buy Right Now - The Motley Fool
Shareholders that lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - AccessWire
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Dexcom COO sells shares worth over $51,000 By Investing.com - Investing.com Australia
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 426 Shares of Stock - MarketBeat
Dexcom COO sells shares worth over $51,000 - Investing.com India
Dexcom CFO sells shares worth over $51k - Investing.com India
Dexcom executive sells over $29k in company stock - Investing.com India
Dexcom executive sells over $29k in company stock - Investing.com
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
DXCM INVESTOR ALERT: If You Suffered Losses on Your DexCom, Inc. Investment, Contact BFA Law Before Upcoming October 21 Class Action Deadline - AccessWire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.
Dexcom Inc [DXCM] stock was sold by Brown Michael Jon at the price of US$48020.0 - Knox Daily
Dexcom, Abbott OTC glucose sensors add to busy year for diabetes tech - MedTech Dive
Class Action Filed Against DexCom, Inc. (DXCM)October 21, 2024 Deadline to JoinContact Levi & Korsinsky - AccessWire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Daiwa Securities Group Inc. Raises Stock Holdings in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc.DXCM - Kilgore News Herald
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsDXCM - Kilgore News Herald
Investors who lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - Kilgore News Herald
DexCom, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights – DXCM - AccessWire
From Hero To Zero: DexCom's Big Fall And What's Next (NASDAQ:DXCM) - Seeking Alpha
DexCom, Inc. Securities Fraud Class Action Lawsuit Pending: - GlobeNewswire
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dexcom Inc Stock (DXCM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sylvain Jereme M | EVP, Chief Financal Officer |
Sep 09 '24 |
Sale |
69.15 |
746 |
51,586 |
84,274 |
| Leach Jacob Steven | EVP, Chief Operating Officer |
Sep 09 '24 |
Sale |
69.15 |
746 |
51,586 |
264,915 |
| Brown Michael Jon | EVP, Chief Legal Officer |
Aug 30 '24 |
Sale |
70.00 |
686 |
48,020 |
65,636 |
0.07%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):